ABEONA THERAPEUTICS INC. (NASDAQ:ABEO) Files An 8-K Other Events
Item 8.01. Other Events

On October 16, 2017, Abeona Therapeutics Inc. issued a press release entitled “Abeona Announces $13.85M Grant from Leading Sanfilippo Syndrome Foundations for Clinical Development of MPS III Gene Therapies”. The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The Company entered into an agreement effective October 15, 2017 with Team Sanfilippo Foundation, Stop Sanfilippo Fundación, Foundation Sanfilippo B, Sanfilippo Children’s Foundation, National MPS Society, Red Sanfilippo Foundation, Children’s Medical Research Foundation, Abby Grace Foundation and Fondation Sanfilippo Suisse (collectively, the “Foundations”) to which the Foundations have agreed to provide up to an aggregate $13,875,000 in funding to support a Phase IB clinical trial of the Company’s ABO-102 product candidate for treatment of MPS IIIA and a Phase IB clinical trial of the Company’s ABO-101 product candidate for treatment of MPS IIIB. The funding is subject to the achievement of certain milestones and is expected to occur between 2017 and 2021.

Item 9.01 Financial Statements and Exhibits.

(d) The following exhibits are being filed herewith:

ABEONA THERAPEUTICS INC. Exhibit
EX-99.1 2 tv477036_ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1     Abeona Announces $13.85M Grant from Leading Sanfilippo Syndrome Foundations for Clinical Development of MPS III Gene Therapies   ·Nine global foundations collaborate to grant $13.85 million for the continued advancement of lead Sanfilippo gene therapy programs ·Company receives infusion of an additional $5 million from exercise of outstanding warrants,…
To view the full exhibit click here

About ABEONA THERAPEUTICS INC. (NASDAQ:ABEO)

Abeona Therapeutics, Inc. (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc., is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians. The Company is also developing ABO-201 (scAAV9 CLN3) gene therapy for juvenile Batten disease (JBD), and ABO-301 (AAV LK19 FANCC) for Fanconi anemia (FA) disorder using a clustered, regularly interspaced short palindromic repeats (CRISPR)/Cas9-based gene editing approach to gene therapy program for rare blood diseases. It is developing rare plasma protein therapies, including PTB-101 SDF Alpha (alpha-1 protease inhibitor) for inherited chronic obstructive pulmonary disease. Its product pipeline also consists of MuGard and ProdiGard.